公司股价表现 - Palisade Bio Inc (PALI) 股价大幅上涨83.77%至1.57美元 成交量达143,677,281股 [1] - Ouster Inc (OUSTZ) 股价上涨76.55%至0.09美元 成交量为150,580股 [2] - Ryvyl Inc (RVYL) 股价跃升72.64%至0.511美元 成交量高达231,813,941股 [3] - Klotho Neurosciences Inc (KLTOW) 股价上涨50.11%至0.14美元 成交量为134,508股 [4] 公司特定事件与业务 - Palisade Bio 宣布扩大承销公开发行 以每股0.70美元发行1.71亿股 筹集1.2亿美元资金 用于推进治疗自身免疫、炎症和纤维化疾病的新型疗法 [1] - Ouster 是一家高分辨率激光雷达传感器供应商 其技术服务于汽车、工业、机器人和智能基础设施等行业 [2] - Ryvyl Inc 前身为GreenBox POS 专注于基于区块链的支付解决方案 在软件基础设施领域展现潜力 [3] - Klotho Neurosciences 致力于开发针对关键健康问题的基因疗法产品 其肌萎缩侧索硬化疗法KLTO-202获得美国FDA孤儿药认定 [4] 行业与市场动态 - 股价大幅上涨的公司反映了行业的多样性 涵盖生物技术、医疗保健、技术和金融服务等领域 [5]

Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ: ETNB) at a price of $14.50 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain milestone payments of up to an aggregate of $6.00 per share in cash. The tender offer is being made pursuant to the previously announced merger agreement dated as of September 17, 2025, among Roche Holdi ...

SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share. In a c ...

WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that data will be presented at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in Seattle, Washington on October 22-25, ...

Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targetin ...

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Regencell Bioscience Holdings Limited is one of them. Regencell Bioscience Holdings Limited (NASDAQ:RGC) tops our list for being one of the stocks with insider buying. It is a Hong Kong-based biopharmaceutical company developing Traditional Chinese Medicine (TCM) treatments for neurocognitive disorders such as ADHD and autism spectrum disorder (ASD). A key milestone came on September 21, 2025, when RGC was added to the S ...

Key Points Pfizer signed a deal with the White House to help Americans pay lower prices for prescription drugs. This agreement removes the uncertainty hanging over Pfizer's head related to the Trump administration's policies. However, Pfizer will slash its drug prices for many products. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) announced on Tuesday that it had signed an agreement with the White House that will help Americans pay lower prices for prescription drugs and bolster U.S. ...

Carlsbad, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the pricing of an underwritten public offering of 171,440,559 shares of its common stock (or common stock equivalents) at a public offering price of $0.70 per share (or $0.6999 per common stock equivalent). Lad ...

CALABASAS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the appointment of Dr. Alexandra M. Miller to its scientific advisory board. Dr. Miller is the Chief of the Neuro-oncology Program and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, where she specialize ...

公司近期活动 - 公司将于2025年12月2日至4日在纽约Lotte New York Palace酒店举办的第37届Piper Sandler医疗健康大会上进行演讲并主持机构投资者会议 [1] - 会议期间公司可安排一对一会议 感兴趣的投资者需联系其Piper Sandler代表进行预约 [2] - 演讲回放链接将在公司官网投资者关系板块的“演讲与活动”页面公布 [2] 公司业务与产品管线 - 公司是一家临床阶段生物制药公司 专注于开发针对AL淀粉样变性及其他严重疾病的细胞疗法 [3] - 公司主要候选产品为NXC-201 这是一种空间结构优化的BCMA靶向嵌合抗原受体T细胞疗法 并带有可过滤非特异性激活的“数字过滤器” [3] - NXC-201正在美国多中心研究NEXICART-2中进行评估 该研究针对复发/难治性AL淀粉样变性 采用注册性试验设计 [3] - NEXICART-2研究的主要终点已在2025年美国临床肿瘤学会年会上公布的中期结果中达成 [3] - NXC-201已获得美国FDA授予的再生医学先进疗法资格 以及FDA和欧盟EMA授予的孤儿药资格 [3]